Palisade Bio (PALI) Other Operating Expenses (2010 - 2026)
Palisade Bio (PALI) posted quarterly Other Operating Expenses of -$3.8 million for Q1 2026, down 183.67% year-over-year from $4.6 million in Q1 2025, and down 7.03% quarter-over-quarter from -$3.6 million in Q4 2025.
Palisade Bio (PALI) Other Operating Expenses (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Other Operating Expenses for 10 consecutive years, with -$3.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses fell 183.67% year-over-year to -$3.8 million; the TTM figure through Mar 2026 stood at -$10.1 million (down 84.51% YoY), while the FY2025 annual figure was -$7.6 million, down 38.37% from the prior year.
- Other Operating Expenses eased to -$3.8 million in Q1 2026 per PALI's latest filing, from -$3.6 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $12.5 million in Q4 2024 and bottomed at -$15.1 million in Q3 2024.
- Historically, Other Operating Expenses has averaged -$1.4 million across 5 years, with a median of -$1.4 million in 2024.
- Annual changes were most pronounced in 2024 — Other Operating Expenses surged 911.35% — and 2026, when it slumped 183.67%.
- Palisade Bio's Other Operating Expenses stood at $410000.0 in 2022, then jumped by 200.98% to $1.2 million in 2023, then soared by 911.35% to $12.5 million in 2024, then plunged by 128.61% to -$3.6 million in 2025, then slipped by 7.03% to -$3.8 million in 2026.
- Business Quant data shows PALI's Other Operating Expenses at -$3.8 million in Q1 2026, -$3.6 million in Q4 2025, and -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.69 Mn |
| Mar 31, 2026 | -3.82 Mn |
| Dec 31, 2025 | -3.57 Mn |
| Sep 30, 2025 | -1.52 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | 12.48 Mn |
| Sep 30, 2024 | -15.10 Mn |
| Jun 30, 2024 | -1.48 Mn |
| Mar 31, 2024 | -1.38 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Sep 30, 2022 | 410,000.00 |
| Jun 30, 2021 | 30.12 Mn |
| Dec 31, 2013 | 171.00 |
| Sep 30, 2013 | 293.00 |
| Jun 30, 2013 | 50,636.00 |
| Mar 31, 2013 | 50,093.00 |
| Dec 31, 2012 | 219.00 |
| Sep 30, 2012 | 692.00 |
| Mar 31, 2012 | 2,573.00 |